Rankings / Cognitive

Oveporexton (TAK-861)

Cognitive · Orexin receptor 2 (OX2R) agonist / wakefulness

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

wakefulnessorexin-agonistnarcolepsyinvestigationalawaiting-readout
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Oveporexton (TAK-861) as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

The wakefulness frontier's biggest swing — Takeda's orexin agonist restores the exact signal narcolepsy patients lack instead of stimulating broadly like amphetamine or modafinil.

Typical use: Oral once daily (Phase 3 dosing) — Investigational.

What this is

The wakefulness frontier's biggest swing — Takeda's orexin agonist restores the exact signal narcolepsy patients lack instead of stimulating broadly like amphetamine or modafinil. Phase 3 FirstLight and RadiantLight (NT1, ~270+ patients) met all primary and secondary endpoints, with ~80% reduction in weekly cataplexy and large daytime-sleepiness improvements; >95% of participants continued into the long-term extension. If cleared it is approved only for narcolepsy, but it proves orexin agonism works in humans — opening the door to broader wakefulness/cognitive uses. FDA Priority Review, PDUFA Q3 2026. Industry-sponsored; pivotal peer-reviewed publication pending.

Mechanism

First-in-class oral orexin-2 receptor-selective agonist; directly replaces the orexin signaling lost in narcolepsy type 1 to drive wakefulness and suppress cataplexy — a mechanism distinct from amphetamines and modafinil

Dose & route

Oral once daily (Phase 3 dosing)

Citations

Links go to the source. If a link is dead or you want something re-checked, let me know.

Common questions

Does Oveporexton (TAK-861) work?
Read Off Label rates the evidence for Oveporexton (TAK-861) as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). The wakefulness frontier's biggest swing — Takeda's orexin agonist restores the exact signal narcolepsy patients lack instead of stimulating broadly like amphetamine or modafinil.
Is Oveporexton (TAK-861) safe?
Oveporexton (TAK-861) has a med risk profile in published human data. Legal status: Investigational (FDA NDA accepted, Priority Review; PDUFA Q3 2026 — narcolepsy type 1). This is not medical advice — see the disclaimer.
What is the typical dose for Oveporexton (TAK-861)?
Oral once daily (Phase 3 dosing)
How does Oveporexton (TAK-861) work?
First-in-class oral orexin-2 receptor-selective agonist; directly replaces the orexin signaling lost in narcolepsy type 1 to drive wakefulness and suppress cataplexy — a mechanism distinct from amphetamines and modafinil

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.